Bioethicist: A clinical medical trial is ethically permissible only if it prioritizes patient welfare above the pursuit of scientific discovery. Furthermore, a trial prioritizes patient welfare only if its participants are not subjected to disproportionate physiological risks. Unfortunately, obtaining statistically robust efficacy data in early-stage oncology trials invariably requires administering drug dosages that approach maximum tolerated toxic thresholds. Consequently, none of the early-stage oncology trials currently underway at the Apex Research Institute are ethically permissible.
The conclusion drawn by the bioethicist follows logically if which one of the following is assumed?
- AAny trial that subjects its participants to disproportionate physiological risks must administer drug dosages that approach maximum tolerated toxic thresholds, and all early-stage oncology trials at the Apex Research Institute involve obtaining statistically robust efficacy data.
- BAt least some of the early-stage oncology trials currently underway at the Apex Research Institute require administering drug dosages that approach maximum tolerated toxic thresholds.
- CAny trial that subjects its participants to disproportionate physiological risks fails to prioritize patient welfare above the pursuit of scientific discovery, thereby rendering it ethically impermissible.
- Every early-stage oncology trial currently underway at the Apex Research Institute involves obtaining statistically robust efficacy data, and the administration of drug dosages that approach maximum tolerated toxic thresholds inherently subjects participants to disproportionate physiological risks.Answer
- EAll early-stage oncology trials always require administering drug dosages that approach maximum tolerated toxic thresholds, regardless of the specific research institute conducting them.
Answer
The correct assumption must perfectly bridge two distinct gaps: connecting the Apex trials to the necessity of obtaining robust data, and connecting the administration of toxic dosages to disproportionate physiological risks.
The argument requires a sufficient assumption to prove that all Apex trials are ethically impermissible. By establishing that all Apex trials involve obtaining robust data, we know they must administer near-toxic dosages (from the third premise). By further establishing that near-toxic dosages cause disproportionate physiological risks, the formal chain is complete: Apex trials -> robust data -> near-toxic dosages -> disproportionate risks -> not prioritizing welfare -> not ethically permissible. The correct answer provides both necessary bridges to make the conclusion 100% deductively valid.
Step-by-Step Solution
Key Concept
Formal Logic: Identifying Nested Conditional Gaps in Sufficient Assumption Questions